SynAct Pharma AB (“SynAct”) announced that John Haurum and Terje Kalland had been proposed as new members of the Board of Directors in SynAct. The following is a brief description of the proposed members of the Board of Directors.
Terje Kalland, MD and Ph.D., has more than 30 years of international experience from leading positions in the pharmaceutical industry, including being Senior Vice President of Novo Nordisk A/S, Director of research and development at Biovitrum AB (now SOBI AB), as well as various positions within Pharmacia AB, including Global Head of Oncology Research. Kalland has extensive experience from investment activities, as well as being research director and vice CEO at Karolinska Development AB. He has a background as a Professor of Tumour immunology at Lund University and has experience as a board member and chairman of the board of several listed and unlisted companies in Sweden and internationally.
John Haurum, MD and Ph.D, is a member of the board of several European biotechnology companies, including Synklino ApS. John Haurum was CEO of the English company F-Star for several years, where two clinical studies were initiated in oncology during his leadership and generated more than EUR 200 million in non-dilution income. John Haurum was previously VP Research at ImClone Systems in New York and was also founder and Chief Scientific Officer of Symphogen A/S.
Chairman of the Board Torbjørn Bjerke comments:
“We are delighted that John Haurum and Terje Kalland have been proposed as new members of the Board of Directors in SynAct. Both John and Terje have extensive experience across several areas of the pharmaceutical industry that will be valuable in the further development of Synact’s business.”
Board member Terje Kalland comments:
“SynAct is an exciting company with a new treatment method for inflammatory and autoimmune diseases that possesses great potential. I am pleased to have been proposed to the Board of Directors of SynAct and look forward to being elected and beginning work with the company and the clinical development of AP1189.”
Board member John Haurum comments:
“SynAct has a unique concept that is now entering a new phase. The candidate drug, AP1189, has the potential to become a new treatment method for inflammatory and autoimmune diseases, which, unlike most of today’s drugs, does not inhibit the body’s immune system but instead stimulates the immune healing mechanisms.”
For further information about SynAct Pharma AB, please contact:
Jeppe Øvlesen
CEO, SynAct Pharma AB
Telephone: +45 28 44 75 67
E-mail: [email protected]
Thomas Jonassen
CSO, SynAct Pharma AB
Telephone: +45 40 15 66 69
E-mail: tj@synactpharma.com